Critical Signal Transduction Pathways in CLL

被引:11
作者
Ghosh, Asish K. [1 ]
Kay, Neil E. [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源
ADVANCES IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2013年 / 792卷
关键词
CLL; Signal transduction; RTK; Non-RTK; Apoptosis; Kinase inhibitor; Therapy; CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; MARROW MICROVESSEL DENSITY; INCREASED SERUM-LEVELS; SRC-FAMILY KINASES; FACTOR-I RECEPTOR; B-CELLS; C-MET; DEPENDENT REGULATION;
D O I
10.1007/978-1-4614-8051-8_10
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.
引用
收藏
页码:215 / 239
页数:25
相关论文
共 157 条
[1]
Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells [J].
Abrams, Simon T. ;
Brown, Benjamin R. B. ;
Zuzel, Mirko ;
Slupsky, Joseph R. .
BLOOD, 2010, 115 (22) :4447-4454
[2]
Structure and function of the type 1 insulin-like growth factor receptor [J].
Adams, TE ;
Epa, VC ;
Garrett, TPJ ;
Ward, CW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) :1050-1093
[3]
Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2 [J].
Afzal, AR ;
Rajab, A ;
Fenske, CD ;
Oldridge, M ;
Elanko, N ;
Ternes-Pereira, E ;
Tüysüz, B ;
Murday, VA ;
Patton, MA ;
Wilkie, AOM ;
Jeffery, S .
NATURE GENETICS, 2000, 25 (04) :419-422
[4]
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL) [J].
Aguayo, A ;
Manshouri, T ;
O'Brien, S ;
Keating, M ;
Beran, M ;
Koller, C ;
Kantarjian, H ;
Rogers, A ;
Albitar, M .
LEUKEMIA RESEARCH, 2001, 25 (04) :279-285
[5]
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].
Amrein, Philip C. ;
Attar, Eyal C. ;
Takvorian, Tak ;
Hochberg, Ephraim P. ;
Ballen, Karen K. ;
Leahy, Kathleen M. ;
Fisher, David C. ;
LaCasce, Ann S. ;
Jacobsen, Eric D. ;
Armand, Philippe ;
Hasserjian, Robert P. ;
Werner, Lillian ;
Neuberg, Donna ;
Brown, Jennifer R. .
CLINICAL CANCER RESEARCH, 2011, 17 (09) :2977-2986
[6]
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis [J].
Angelillo-Scherrer, A ;
de Frutos, PG ;
Aparicio, C ;
Melis, E ;
Savi, P ;
Lupu, F ;
Arnout, J ;
Dewerchin, M ;
Hoylaerts, MF ;
Herbert, M ;
Collen, D ;
Dahlbäck, B ;
Carmeliet, P .
NATURE MEDICINE, 2001, 7 (02) :215-221
[7]
Assessment of Bone Marrow Microvessel Density in Chronic Lymphocytic Leukemia [J].
Antic, Darko ;
Jovanovic, Maja Perunicic ;
Fekete, Marija Dencic ;
Cokic, Vladan .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2010, 18 (04) :353-356
[8]
All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells [J].
Bairey, O ;
Boycov, O ;
Kaganovsky, E ;
Zimra, Y ;
Shaklai, M ;
Rabizadeh, E .
LEUKEMIA RESEARCH, 2004, 28 (03) :243-248
[9]
Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia [J].
Bairey, O ;
Zimra, Y ;
Shaklai, M ;
Rabizadeh, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :400-406
[10]
The IGF-I receptor in cancer research [J].
Baserga, R .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :1-6